XyloCor Therapeutics
A. Brian Davis is a seasoned financial executive, with over 15 years of experience as a CFO for publicly traded, commercial, and clinical‑stage biopharmaceutical companies, and nearly 30 years as a financial professional in the life sciences industry. Mr. Davis has raised over $600 million in public and private equity financings, including leading an initial public offering, and nearly $200 million in debt financings. Most recently, he was CFO at Verrica Pharmaceuticals, where he held managerial responsibility for executing equity and debt financings, analyst and shareholder relations, financial aspects of commercial launch preparation, business development, finance, accounting, tax, and treasury.
This person is not in any teams
This person is not in any offices
XyloCor Therapeutics
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.